Generare Secures €20M to Unlock Microbial Chemistry Secrets
▼ Summary
– Generare, a Paris-based techbio company, has raised €20 million in a Series A funding round co-led by Alven and Daphni.
– The company screens microbial genomes to discover novel small molecules, estimating that 97% of this molecular chemistry remains uncharacterized.
– Its platform uses high-throughput technology to identify, express, and characterize bioactive compounds from tens of thousands of genomes.
– The company claims to have characterized over 200 previously unknown molecules and asserts a historically successful hit rate.
– The new funding will scale its molecule library ten-fold by 2027 and nearly double its international team of 25 specialists.
A Parisian biotech firm has secured a major investment to decode a vast, untapped chemical library hidden within the world’s microbes. Generare has raised €20 million in a Series A funding round to dramatically scale its platform for discovering novel bioactive molecules. The financing was co-led by venture firms Alven and Daphni, with participation from all existing investors.
The company’s founders, CEO Guillaume Vandenesch and CSO Dr. Vincent Libis, leverage a decade of specialized research. Dr. Libis’s background includes synthetic biology work at Rockefeller University, leadership of an INSERM research team, and co-founding another biotech firm. This latest capital infusion follows a €5 million seed round completed in 2024.
Generare’s mission targets a significant scientific gap. Microorganisms like bacteria and fungi possess genetic blueprints for countless small molecules, the products of three billion years of evolution. While these natural compounds have historically yielded blockbuster drugs like penicillin, traditional discovery methods have accessed less than 3% of this potential. An estimated 97% of microbial molecular chemistry remains uncharacterised.
To bridge this gap, the company employs a high-throughput platform rooted in academic research. It screens tens of thousands of microbial genomes, pinpointing genetic sequences likely to produce valuable compounds. These sequences are then expressed and the resulting molecules are analyzed for their structure and biological function. The firm states its validated approach has already identified over 200 previously unknown small molecules.
Company disclosures highlight an ambitious pace of discovery. Generare asserts that in 2025 it characterized five times more novel molecules than the rest of the field combined, achieving a hit rate comparable to historically successful drug discovery programs. While these figures are self-reported, the underlying cloning and biosynthetic methodology has been peer-reviewed and was previously detailed in industry coverage.
The new capital will fuel aggressive expansion. Generare plans a ten-fold scale-up of its molecule library by 2027, aiming to grow from roughly 200 compounds to over 2,000, with a long-term goal of 10,000. To support this growth, the current 25-person international team will nearly double in size. The company is already engaged in partnerships with several major global pharmaceutical and agrochemical firms.
Generare’s strategy underscores a critical need in modern drug discovery. As the industry notes, AI models trained on familiar chemical data tend to produce similar results. By feeding these algorithms a stream of truly novel, biologically active structures, the potential for groundbreaking therapeutic and agricultural outputs increases substantially. The company’s scientific advisory board, which includes former Novartis executive Dr. Frank Petersen and microbial genomics expert Professor Nadine Ziemert, guides this data-centric approach.
(Source: The Next Web)
